Compare Abeona Therapeutics Inc (ABEO) vs Upstart Holdings Inc (UPST) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Upstart Holdings Inc — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Upstart Holdings Inc trades at $31.34 (market cap $3.16B). The key difference: Upstart Holdings Inc is far larger — about 8.5× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Upstart Holdings Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | UPST | |
|---|---|---|
Market Cap | $373.32M | $3.16B |
Sector | Health | Financials |
52-Week High | $7.23 | $84.13 |
52-Week Low | $4.17 | $24.22 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Upstart trades at $33.06, down 4.95% today, with mixed technical signals showing a bullish moving average trend but neutral oscillators. The company reported $1.02B revenue in 2025 with net income of $53.60M, marking a return to profitability after previous losses. Recent news highlights AI lending growth and a $600M funding deal with Neuberger (Business Wire, June 24, 2026).
Outlook is cautiously optimistic with a consensus price target of $43.00 (45% buy ratings), but risks include volatile cash flows, high debt-to-asset ratio of 61.48%, and execution challenges in expanding auto/home lending products. The stock offers upside if AI-driven originations sustain growth, yet remains sensitive to funding and macroeconomic conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Upstart Holdings Inc
Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. The revenue of the company is primarily comprised of fees paid by banks.
Read more on UPST →
